Model | Cell type or species | Inhibitor | Parameters assessed | Functional effects | Reference |
---|---|---|---|---|---|
In vitro assay | C-EE, C-ES | PKF 115-584 | Cell proliferation | C-EE, C-ES, E-EE, E-ES, EnE and EnS: significantly inhibited vs. non-treated cells | [4] |
E-EE, E-ES | CGP049090 | ||||
EnE, EnS | |||||
C-EE, C-ES | PKF 115-584 | Cell migration | C-EE, C-ES, E-EE, E-ES, EnE and EnS: significantly inhibited vs. non-treated cells | [4] | |
E-EE, E-ES | |||||
EnE, EnS | |||||
C-EE, C-ES | PKF 115-584 | Cell invasion | C-EE, C-ES, E-EE, E-ES, EnE and EnS: significantly inhibited vs. non treated cells | [4] | |
E-EE, E-ES | |||||
EnE, EnS | |||||
C-EE, C-ES | PKF 115-584 | Tcf/β-catenin target genes (Cyclin D1, Survivin, c-Myc, MMP2, MMP9) | C-EE, C-ES, E-EE, E-ES, EnE and EnS: cyclin D1, Survivin, MMP2 and MMP9 mRNA: significantly decreased vs. non-treated cells | [4] | |
E-EE, E-ES | |||||
EnE, EnS | |||||
Total form of MMP-9 in E-EE or E-ES: significantly decreased vs. C-EE or C-ES | |||||
Active forms of MMP-2 in EnE: significantly decreased vs. E-EE | |||||
Total form of MMP-9 in EnS: significantly decreased vs. E-ES | |||||
E-ES, EnS | PKF 115-584 | Fibrotic markers (αSMA, Col-I, CTGF, and FN) | E-ES, EnS: αSMA, Col-I, CTGF, and FN mRNA (with or without TGF ß1 stimulation): significantly decreased vs. non-treated cells | [4] | |
CGP049090 | EnS: percentage of αSMA-positive cells: significantly decrased vs. non-treated cells | ||||
E-ES, EnS | PKF 115-584 | Collagen gel contraction | E-ES, EnS: significantly decreased vs. non-treated cells | [5] | |
CGP049090 | |||||
In vivo assay | Mouse (female Swiss nude mice) | CGP049090 | Severity of fibrosis in endometriotic implants assessed by Sirius Red or Masson Trichrome stains | Staining scores for Sirius Red or Masson Trichrome stains: significantly lower vs. non-treated mice | [5] |